fashion -WSS

fashion

author：fashion 2025-08-19 15:01:42 - browse：3895

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Trump surgeon general acknowledges mistakes during Covid

Wikipedia

WSS

What drug price negotiations mean for Medicare Part D

Amazon on where the company's health care bets are headed next

What drug price negotiations mean for Medicare Part D

Illumina names Agilent executive as new CEO

The 10 drugs up first for Medicare price negotiation

Statins may not be needed by millions of people, study suggests

hotspot

fashion

explore

Affirmative action in medical school literally saved lives

What drug price negotiations mean for Medicare Part D

DIEP, the 'gold standard' of breast reconstruction, is under threat

Weighted lottery helped low

Walensky prepares to leave CDC — and Congress — behind

California wildfire smoke linked to 52,000 early deaths, study says

Anesthesiologist group: stop taking Ozempic before surgery

How to protect patients from sexual assault

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medical device trials still don't enroll enough women, study finds

leisure time

Cheap, fast test for Zika and dengue could cost just $1

Humana sues Biden admin over Medicare Advantage audit rule

Snackable artificial intelligence, expert AI, and the pharma industry

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

'Essentially witchcraft:' A former naturopath takes on the field

Listen: Biogen's potential pivot, & Illumina's next chapter

Wikipedia

knowledge

explore

entertainment